Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
about
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinibSequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma.Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceRoles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimenPIK3CA gene amplification and PI3K p110α protein expression in breast carcinoma.Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
P2860
Q33933626-504FBE56-83A0-4691-BF0D-1B6324799855Q35082400-667B15B8-3DEC-449A-8A1A-5B5940D71F78Q36100503-30D7A67F-E187-433E-AAC8-A75837B8968BQ36250585-F1FEF918-C842-4DBC-AFFB-F32F97B1D8A5Q36375442-8B736F8B-AEE2-409A-BA43-E9DC5A3A0129Q37730266-5A90AF05-2B22-4B92-9235-257904A3ACAFQ37886009-CEE1568A-2B14-4AF3-8048-7A04A29E4692
P2860
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Approaches and limitations of ...... velopment of targeted therapy.
@en
Approaches and limitations of ...... velopment of targeted therapy.
@nl
type
label
Approaches and limitations of ...... velopment of targeted therapy.
@en
Approaches and limitations of ...... velopment of targeted therapy.
@nl
prefLabel
Approaches and limitations of ...... velopment of targeted therapy.
@en
Approaches and limitations of ...... velopment of targeted therapy.
@nl
P2093
P2860
P1476
Approaches and limitations of ...... velopment of targeted therapy.
@en
P2093
Andrew Strahs
Anna Berkenblit
Charles Zacharchuk
Christina M Coughlin
Daniel S Johnston
Jason Hill
Jay M Feingold
Michael E Burczynski
Sarah Bacus
P2860
P2888
P356
10.1007/S10549-010-1108-4
P407
P577
2010-08-28T00:00:00Z